COMMUNIQUÉS West-GlobeNewswire
 
      -   
  mediCAD® 8 Revolutionizes Orthopedic and Trauma Planning with Intelligent AI Integration26/10/2025
-   
  Polpharma Group annonce un changement de direction – Sebastian Szymanek nommé nouveau président26/10/2025
-   
  Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 202525/10/2025
-   
  Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions25/10/2025
-   
  Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets25/10/2025
-   
  Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease25/10/2025
-   
  Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 202525/10/2025
-   
  Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases25/10/2025
-   
  Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 202525/10/2025
-   
  ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium25/10/2025
-   
  Aletheia Capital Endeavours Launches RepIntel, a Campaign-Grade Platform to Accelerate Global Access to Therapies25/10/2025
-   
  Prenetics Global Limited Announces Proposed Public Offering25/10/2025
-   
  Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences24/10/2025
-   
  Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty24/10/2025
-   
  Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)24/10/2025
-   
  Enzon and Viskase Announce Amendment to Merger Agreement24/10/2025
-   
  Pennant Announces Third Quarter 2025 Earnings Release and Call24/10/2025
-   
  Surgery Partners, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Details25/10/2025
-   
  Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference24/10/2025
Pages